Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Targeting p53 Improves Drug Resistance in Mantle Cell Lymphoma By Regulating Mitophagy-Dependent Ferroptosis

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2024-205447

Published: 2024

Journal Articles

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Yuan Yang, Ping Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5753.

https://doi.org/10.1182/blood-2024-204870

Published: 2024

Journal Articles

Symptom Burden and Health-Related Quality of Life in Patients with Aggressive Non-Hodgkin Lymphoma in China: A Cross-Sectional Study

Jiayue Jin, Simeng Ren, Wei Zhang, Ping Yang, Jingqi Yang, Hongkun Xu, Baojin Han, Wenzheng Zhang, Jie - Liu

Blood (2024) 144 (Supplement 1): 6437.

https://doi.org/10.1182/blood-2024-194707

Published: 2024

Journal Articles

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Yingtong Chen, Ping Yang, Weilong Zhang, Jing Wang, Shuang Gao, Yuan Yang, Shuozi Liu, Chunyuan Li, Hongmei Jing

Blood (2024) 144 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2024-205492

Published: 2024

Journal Articles

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Lingli Wang, Jinjie Gao, Wei Wan, Fei Dong, Jing Wang, Weilong Zhang, Ping Yang, Lan Ma, Wei Zhao, Jijun Wang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6340.

https://doi.org/10.1182/blood-2024-205570

Published: 2024

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Chunyuan Li, Jinjie Gao, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6339.

https://doi.org/10.1182/blood-2024-205068

Published: 2024

Journal Articles

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Ping Yang, Chunyuan Li, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6338.

https://doi.org/10.1182/blood-2024-205042

Published: 2024

Journal Articles

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Xiaoyu Hao, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6337.

https://doi.org/10.1182/blood-2024-204938

Published: 2024

Journal Articles

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Ping Yang, Chunyuan Li, Shuozi Liu, Yuan Yang, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6305.

https://doi.org/10.1182/blood-2024-205002

Published: 2024

Journal Articles

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

Ping Yang, Chunyuan Li, Yuan Yang, Shuozi Liu, Jing Wang, Yingtong Chen, Weilong Zhang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6303.

https://doi.org/10.1182/blood-2024-204939

Published: 2024

Journal Articles

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Shuozi Liu, Shaowei Zhou, Weilong Zhang, Jing Wang, Lingli Wang, Chunyuan Li, Yingtong Chen, Wenxin Qi, Ping Yang, Hongmei Jing

Blood (2024) 144 (Supplement 1): 6301.

https://doi.org/10.1182/blood-2024-204877

Published: 2024

Journal Articles

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Ajlan Al Zaki, Margie Sutton, Abdur Rehman, Cao Cuong Le, Seth Gammon, Arianna Napoli, Ping Yang, Neeraj Y. Saini, Sairah Ahmed, Ghayas C. Issa, Partow Kebriaei, Michael Davies, Elizabeth J. Shpall, Jeena Varghese, Lesley Flynt, Sattva S. Neelapu, David Piwnica-Worms

Blood (2024) 144 (Supplement 1): 3428.

https://doi.org/10.1182/blood-2024-211204

Published: 2024

Journal Articles

Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 4313.

https://doi.org/10.1182/blood-2024-201637

Published: 2024

Journal Articles

The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

Blood (2024) 144 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2024-200874

Published: 2024

Journal Articles

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Yingtong Chen, Hongmei Jing

Blood (2023) 142 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2023-184372

Published: 2023

Journal Articles

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Xiaoyan Ke, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2023-183096

Published: 2023

Journal Articles

The Different Impacts of an MRD-Guided Protocol on Relapse of Childhood Acute Lymphoblastic Leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

Blood (2023) 142 (Supplement 1): 1462.

https://doi.org/10.1182/blood-2023-186805

Published: 2023

Journal Articles

ATRA Can Correct Impaired Proplatelet Formation By Regulating HIF-1α/SPHK2/S1P Axis in ITP

Qiusha Huang, FengQi Liu, Qi Chen, Gaochao Zhang, Xueyan Sun, Chen-Cong Wang, Li-Ping Yang, Kaiyan Liu, Xiaojun Huang, Xiaohui Zhang

Blood (2023) 142 (Supplement 1): 3940.

https://doi.org/10.1182/blood-2023-184311

Published: 2023

Journal Articles

Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma

Chunyuan Li, Jingjing Yin, Yue Yuan, Ping Yang, Hui Liu, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2023-181497

Published: 2023

Journal Articles

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Ping Yang, Shuozi Liu, Weilong Zhang, Jing Wang, Hongmei Jing

Blood (2023) 142 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2023-184348

Published: 2023

NARROW

Targeting p53 Improves Drug Resistance in Mantle Cell Lymphoma By Regulating Mitophagy-Dependent Ferroptosis

UHRF1 Is a Promising Therapy Target in Aggressive Mantle Cell Lymphoma

Symptom Burden and Health-Related Quality of Life in Patients with Aggressive Non-Hodgkin Lymphoma in China: A Cross-Sectional Study

Selinexor Synergizes with Decitabine in Mantle Cell Lymphoma through MAPK Signaling Pathway

Prognostic Significance of POD24 and Monoclonal Paraproteinemia in Extranodal MZL

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Treatment Outcomes of BTK Inhibitors and Venetoclax with/without Anti-CD20 Monoclonal Antibody in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Real-World Experience

Central Nervous System Involvement in Mantle Cell Lymphoma: Clinical Features, Prognostic Factors and Outcomes from Multi-Centers in China

A Comprehensive Stratification Integrated the Clinical, Pathological, and Molecular Biological Features to Distinguish High-Risk Mantle Cell Lymphoma

Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors

TP53 Mutation Heterogeneity Reveals Distinct Prognoses in Mantle Cell Lymphoma

Imaging Activated Innate Immune Myeloid Cells in Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Following CAR T-Cell Therapy

Clinical Application for Modification of the 2022 European Leukemianet Genetic Risk Stratification in Pediatric Acute Myeloid Leukemia

The Impacts of Circulating Lymphoblasts and the Day of the First Triple Intrathecal Therapy on the CNS Outcomes of Childhood ALL: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

The Efficacy of Obinutuzumab Combined with Pomalidomide and Covalent Btki for the Treatment of TP53 Mutated Mantle Cell Lymphoma (MCL): A Prospective, Open-Label, Single-Arm Study

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

The Different Impacts of an MRD-Guided Protocol on Relapse of Childhood Acute Lymphoblastic Leukemia: The Report of Taiwan Pediatric Oncology Group (TPOG)-ALL-2013

ATRA Can Correct Impaired Proplatelet Formation By Regulating HIF-1α/SPHK2/S1P Axis in ITP

Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma

Phase I Study of a CD19-Directed CAR-T Cell Therapy for Relapsed/Refractory Mantle Cell Lymphomas(MCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only